A Food and Drug Administration advisory committee today recommended approval of a new type of experimental cholesterol-fighting drug that could be more potent and carry fewer side effects than statins, which are among the most prescribed drugs in the United States.
The agency will likely follow the advisory committee's advice when it decides whether to approve the drug, alirocumab (Praluent) from Sanofi Specific Action: and Regeneron Pharmaceuticals Inc., for patients later this summer.
On Wednesday, the advisory committee will discuss a second drug in the same class, evolocumab (Repatha) from Amgen Inc.
The drugs represent the most important new class of cholesterol-lowering medications since the first statin was approved in 1987. Seven statins are available in the United States, including Zocor, Lipitor and Crestor. Ref. CNN
New way to treat cholesterol may be on the horizon. A breakthrough discovery could change the way we treat cholesterol. Researchers found new evidence that challenges a 40-year notion of how fast we eliminate it from our bodies. This accidental discovery reveals a new pathway in the cholesterol-elimination chain that will be key to developing new drugs to lower cholesterol. Source 8x.